Catherine Owen Net Worth

The estimated Net Worth of Catherine E. Owen is at least $1.82 Thousand dollars as of 13 June 2024. Ms. Owen owns over 1,976 units of OptiNose Inc stock worth over $1,818 and over the last 4 years she sold OPTN stock worth over $0. In addition, she makes $0 as Director at OptiNose Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Ms. Owen OPTN stock SEC Form 4 insiders trading

Catherine has made over 1 trades of the OptiNose Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently she exercised 1,976 units of OPTN stock worth $1,818 on 13 June 2024.

The largest trade she's ever made was exercising 1,976 units of OptiNose Inc stock on 13 June 2024 worth over $1,818. On average, Catherine trades about 220 units every 0 days since 2020. As of 13 June 2024 she still owns at least 1,976 units of OptiNose Inc stock.

You can see the complete history of Ms. Owen stock trades at the bottom of the page.

Catherine Owen biography

Catherine E. Owen serves as Director of the Company. Catherine currently serves as Senior Vice President, Major Markets at Bristol-Myers Squibb, overseeing commercial operations for the business in 18 countries including Japan, Germany, France, and others across Europe. She joined BMS in 2019 from Johnson & Johnson, where she served most recently as President of Janssen Immunology North America, which launched new products in Crohn’s disease and psoriasis and led the development of J&J’s biosimilars strategy. Prior to leading Immunology, she was the President of the Infectious Diseases business in the US, responsible for the HIV, RSV, Flu, and Hepatitis B pipeline. Prior to that she worked in various functions and businesses at J&J and led the launches of multiple products in both Europe and the US. Catherine began her career in the pharmaceutical industry in 1992 at AstraZeneca in London as a production support pharmacist. Catherine earned her Bachelor of Science degree in pharmacy from the University of Manchester and completed her registered pharmacy degree and was a member of the Royal Pharmaceutical Society, MRPhs. In 2019, in recognition of her efforts as a developer of talent, the Healthcare Businesswomen's Association (HBA) named Owen an HBA Luminary.

What's Catherine Owen's mailing address?

Catherine's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at OptiNose Inc

Over the last 19 years, insiders at OptiNose Inc have traded over $144,654,703 worth of OptiNose Inc stock and bought 116,688 units worth $814,936 . The most active insiders traders include Sriram Venkataraman, Capital Partners Ii Gp, Llc..., and Rajat Rai. On average, OptiNose Inc executives and independent directors trade stock every 26 days with the average trade being worth of $106,645. The most recent stock trade was executed by Anthony J Krick on 17 July 2024, trading 6,845 units of OPTN stock currently worth $7,803.

What does OptiNose Inc do?

optinose, inc., established in 2010 and headquartered in yardley, pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ent and allergy specialists. our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. we are unified by a shared mission: to improve lives. we do this while also creating great value for the healthcare system and great outcomes for our stakeholders. as innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. we operate with an overarching commitment to doing what is right. we are committed to working together as a team that chooses to live every day by core company values that guide our daily behaviors, creating a fo

Complete history of Ms. Owen stock trades at Agios Pharmaceuticals Inc and OptiNose Inc

OptiNose Inc executives and stock owners

OptiNose Inc executives and other stock owners filed with the SEC include:

• Peter Miller,
  Chief Executive Officer, Director
• Ramy Mahmoud,
  President, Chief Operating Officer
• Michael Marino,
  Chief Legal Officer and Corporate Secretary
• Peter K. Miller,
  CEO & Director
• Keith Goldan,
  Chief Financial Officer
• Dr. Ramy A. Mahmoud M.D., M.P.H.,
  Pres & COO
• Michael F. Marino,
  Chief Legal Officer & Corp. Sec.
• Keith Alan Goldan,
  Chief Financial Officer
• Victor M. Clavelli,
  Chief Commercial Officer
• Michael F. Marino Esq.,
  Chief Legal Officer & Corp. Sec.
• Joseph Scodari,
  Independent Chairman of the Board
• Sandra Helton,
  Independent Director
• Wilhelmus Groenhuysen,
  Independent Director
• William Doyle,
  Independent Director
• Jonathan Neely,
  VP Investor Relations and Business Operations
• Catherine Owen,
  Director
• Victor Clavelli,
  Chief Commercial Officer
• Anthony Krick,
  VP & Chief Accounting Officer
• Michele Janis MBA,
  VP & Acting CFO
• Dr. Per Gisle Djupesland M.D., Ph.D.,
  Co-Founder & Chief Scientific Officer of OptiNose AS
• Helena Kyttari Djupesland,
  Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)
• John Messina,
  Sr. VP of Clinical Devel. & Medical Affairs
• Karen E. Brophy,
  VP of HR
• Paul Mastrapa,
  CFO
• John N Kapoor,
  Director
• Edward A Blechschmidt,
  Director
• Leo Henikoff,
  Director
• Kenneth Abramowitz,
  Director
• Jerome Sheldon,
  Director
• Rajat Rai,
  CEO
• Joseph Bonaccorsi,
  Secretary
• Richard M Smith,
  President & COO
• Capital Partners Ii Gp, Llc...,
  
• Ventures Llctkwd Ventures L...,
  
• Fund Lp Entrepreneurs Fund ...,
  
• Rick Bierly,
  Director
• Sriram Venkataraman,
  Director
• Larry G Pickering,
  Director
• Thomas Edward Gibbs,
  Chief Commercial Officer
• Joshua Alexander Tamaroff,
  Director
• Robert P O'neil,
  Director
• Ventures Llc Wfd,
  10% owner
• Ventures Llc Tkwd,
  10% owner
• Anthony J Krick,
  Chief Accounting Officer
• Tomas J. Heyman,
  Director
• Kyle Dempsey,
  Director
• Eric Bednarski,
  Director
• R John Fletcher,
  Director
• Paul Jr. Spence,
  Chief Commercial Officer
• Michele Janis,
  Acting Chief Financial Officer